Comparative Pharmacology
Head-to-head clinical analysis: DANOCRINE versus TESTOSTERONE CYPIONATE ESTRADIOL CYPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANOCRINE versus TESTOSTERONE CYPIONATE ESTRADIOL CYPIONATE.
DANOCRINE vs TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.
Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.
100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.
Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life: 10–30 hours (mean 15 hours); clinically, steady-state reached after 2–4 days.
Testosterone cypionate: approximately 8 days; estradiol cypionate: approximately 8-10 days. Clinical context: steady-state reached in 3-5 weeks.
Renal (metabolites, ~50%), biliary/fecal (~30%), unchanged drug minimal.
Renal (90% as glucuronide and sulfate conjugates, less than 5% as unchanged drug); fecal (approximately 10%).
Category C
Category D/X
Androgen/Antigonadotropin
Androgen